Dan Leonard
Stock Analyst at UBS
(2.44)
# 2,345
Out of 4,905 analysts
291
Total ratings
54.04%
Success rate
-5.96%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Downgrades: Neutral | $500 → $460 | $414.75 | +10.91% | 16 | Jul 9, 2025 | |
| MTD Mettler-Toledo International | Upgrades: Buy | $1,530 → $1,350 | $1,194.85 | +12.98% | 9 | May 20, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $12 | $12.15 | -1.23% | 5 | May 13, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $95 → $70 | $52.02 | +34.56% | 11 | May 9, 2025 | |
| BRKR Bruker | Maintains: Neutral | $57 → $45 | $40.55 | +10.97% | 11 | May 8, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $185 | $160.63 | +15.17% | 14 | May 7, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $246.40 | +25.81% | 20 | May 2, 2025 | |
| BIO.B Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $250.66 | +23.68% | 20 | May 2, 2025 | |
| GH Guardant Health | Maintains: Buy | $65 → $70 | $46.46 | +50.67% | 9 | May 1, 2025 | |
| RVTY Revvity | Upgrades: Buy | $145 → $115 | $93.26 | +23.31% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $240 | $190.05 | +26.28% | 17 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $99.99 | -0.99% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $13.28 | +88.25% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $154.48 | +19.76% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $7.19 | +25.17% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $420 → $350 | $311.87 | +12.23% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 | $10.10 | +58.42% | 9 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $17.78 | +96.85% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $113.99 | +31.59% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $96.14 | +108.03% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.43 | +352.67% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $138.90 | -49.60% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $50.46 | +78.36% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $10.39 | -32.63% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $287.53 | +19.99% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $143.54 | +81.13% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $166.91 | -13.13% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $63.99 | +40.65% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $48.36 | +31.62% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $243.72 | +39.50% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $24.90 | -3.61% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.47 | +683.00% | 12 | Aug 14, 2019 |
Thermo Fisher Scientific
Jul 9, 2025
Downgrades: Neutral
Price Target: $500 → $460
Current: $414.75
Upside: +10.91%
Mettler-Toledo International
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,194.85
Upside: +12.98%
10x Genomics
May 13, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $12.15
Upside: -1.23%
Bio-Techne
May 9, 2025
Maintains: Buy
Price Target: $95 → $70
Current: $52.02
Upside: +34.56%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $57 → $45
Current: $40.55
Upside: +10.97%
IQVIA Holdings
May 7, 2025
Maintains: Buy
Price Target: $255 → $185
Current: $160.63
Upside: +15.17%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $246.40
Upside: +25.81%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $250.66
Upside: +23.68%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $46.46
Upside: +50.67%
Revvity
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $93.26
Upside: +23.31%
Apr 23, 2025
Maintains: Buy
Price Target: $275 → $240
Current: $190.05
Upside: +26.28%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $99.99
Upside: -0.99%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $13.28
Upside: +88.25%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $154.48
Upside: +19.76%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $7.19
Upside: +25.17%
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $311.87
Upside: +12.23%
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $10.10
Upside: +58.42%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $17.78
Upside: +96.85%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $113.99
Upside: +31.59%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $96.14
Upside: +108.03%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.43
Upside: +352.67%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $138.90
Upside: -49.60%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $50.46
Upside: +78.36%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $10.39
Upside: -32.63%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $287.53
Upside: +19.99%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $143.54
Upside: +81.13%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $166.91
Upside: -13.13%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $63.99
Upside: +40.65%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $48.36
Upside: +31.62%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $243.72
Upside: +39.50%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $24.90
Upside: -3.61%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.47
Upside: +683.00%